Design and synthesis of orally bioavailable aminopyrrolidinone histone deacetylase 6 inhibitors

Journal of Medicinal Chemistry

Volumn 58, Issue 6, 2015, Pages 2809-2820

  Lin, Xianfeng ^a   Chen, Wenming ^a   Qiu, Zongxing ^a   Guo, Lei ^a   Zhu, Wei ^a   Li, Wentao ^a   Wang, Zhanguo ^a   Zhang, Weixing ^a   Zhang, Zhenshan ^a   Rong, Yiping ^a   Zhang, Meifang ^a   Yu, Lingjie ^a   Zhong, Sheng ^a   Zhao, Rong ^a   Wu, Xihan ^a   Wong, Jason C ^a   Tang, Guozhi ^a  

^a Roche Innovation Center Shanghai   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 PYRROLIDONE DERIVATIVE; 3 CHLORO 4 [[1 (4 CHLOROPHENYL) 2 OXOPYRROLIDIN 3 YL]AMINO]BENZENECARBOHYDROXAMIC ACID; 3 [[4 (3 PYRIDYL)PYRIMIDIN 2 YL]AMINO] 1,2,3,4 TETRAHYDROQUINOLINE 6 CARBOHYDROXAMIC ACID; 4 (2 OXO 1 PHENYLPYRROLIDIN 3 YL)OXYBENZENECARBOHYDROXAMIC ACID; 4 [( 2 OXO 1 PHENYLPYRROLIDIN 3 YL) AMINO]BENZENECARBOHYDROXAMIC ACID; 4 [(1 BENZYL 2 OXOPYRROLIDIN 3 YL)AMINO]BENZENECARBOHYDROXAMIC ACID; 4 [(3 METHYL 2 OXO 1 PHENYLPYRROLIDIN 3 YL)AMINO]BENZENECARBOHYDROXAMIC ACID; 4 [(5 OXO 1 PHENYLPYRROLIDIN 3 YL)AMINO]BENZENECARBOHYDROXAMIC ACID; 4 [METHYL(2 OXO 1 PHENYLPYRROLIDIN 3 YL)AMINO]BENZENECARBOHYROXAMIC ACID; 4 [[1 (2 CHLOROPHENYL) 2 OXOPYRROLIDIN 3 YL]AMINO]BENZENECARBOHYDROXAMIC ACID; 4 [[1 (2 NAPHTHYL ) 2 OXOPYRROLIDIN 3 YL]AMINO]BENZENECARBOHYDROXAMIC ACID; 4 [[1 (3 CHLOROPHENYL) 2 OXOPYRROLIDIN 3 YL]AMINO]BENZENECARBOHYDROXAMIC ACID; 4 [[1 (4 CHLOROPHENYL) 2 OXOPYRROLIDIN 3 YL]AMINO] 2 FLUOROBENZENECARBOHYDROXAMIC ACID; 4 [[1 (4 CHLOROPHENYL) 2 OXOPYRROLIDIN 3 YL]AMINO]BENZENECARBOHYDROXAMIC ACID; 4 [[1 (4 CHLOROPHENYL) 3 METHYL 2 OXOPYRROLIDIN 3 YL]AMINO]BENZENECARBOHYDROXAMIC ACID; 4 [[1 (4 CHLOROPHENYL)PYRROLIDIN 3 YL]AMINO]BENZENECARBOHYDROXAMIC ACID; 4 [[1 (4 CYNAOPHENYL) 2 OXOPYRROLIDIN 3 YL]AMINO]BENZENECARBOHYDROXAMIC ACID; 4 [[1 (4 METHYLSULFONYLPHENYL) 2 OXOPYRROLIDIN 3 YL]AMINO]BENZENECARBOHYDROXAMIC ACID; 4 [[1 [3 [2 (DIMETHYLAMINO)ETHOXY]PHENYL] 2 OXOPYRROLIDIN 3 YL]AMINO]BENZENECARBOHYDROXAMIC ACID; 4 [[2 OXO 1 (2 PHENYLETHYL)PYRROLIDIN 3 Y]AMINO]BENZENECARBOHYDROXAMIC ACID; 4 [[3 METHYL 2 OXO 1 (6 QUINOLYL)PYRROLIDIN 3 YL]AMINO]BENZENECARBOHYDROXAMIC ACID; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE INHIBITOR; METHYL GROUP; PROTEIN P21; TETRAHYDROQUINOLINE; TUBULIN; UNCLASSIFIED DRUG; HDAC6 PROTEIN, HUMAN; HISTONE DEACETYLASE; HYDROXAMIC ACID; ISOPROTEIN;

ACETYLATION; ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONFORMATION; DRUG DESIGN; DRUG DEVELOPMENT; DRUG EXPOSURE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG RESEARCH; DRUG SCREENING; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; EC50; ENANTIOMER; ENZYME INHIBITION ASSAY; HUMAN; HUMAN CELL; IC50; METHYLATION; MOLECULAR MODEL; MOUSE; NONHUMAN; PHARMACOKINETICS; STRUCTURE ACTIVITY RELATION; ANIMAL; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; MALE; METABOLISM; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; CELL LINE; DRUG DESIGN; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MALE; MICE; MODELS, MOLECULAR; PROTEIN ISOFORMS; PYRROLIDINONES;

EID: 84925841614     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm502011f     Document Type: Article

References (25)

1. Siedel, C.; Schnekenburger, M.; Dicato, M.; Diederich, M. Histone deacetylase 6 in health and disease Epigenomics 2015, 7, 103-118
2. Yang, P. H.; Zhang, L.; Zhang, Y. J.; Zhang, J.; Xu, W. F. HDAC6: Physiological function and its selective inhibitors for cancer treatment Drug Discoveries Ther. 2013, 7, 233-242
3. Asthana, J.; Kapoor, S.; Mohan, R.; Panda, D. Inhibition of HDAC6 deacetylase activity increases its binding with microtubules and suppresses microtubule dynamic instability in MCF-7 cells J. Biol. Chem. 2013, 288, 22516-22526
4. Kekatpure, V. D.; Dannenberg, A. J.; Subbaramaiah, K. HDAC6 modulates Hsp90 chaperone activity and regulates activation of aryl hydrocarbon receptor signaling J. Biol. Chem. 2009, 284, 7436-7445
5. Zhang, X. H.; Yuan, Z. G.; Zhang, Y. T.; Yong, S.; Salas-Burgos, A.; Koomen, J.; Olashaw, N.; Parsons, J. T.; Yang, X. J.; Dent, S. R.; Yao, T. P.; Lane, W. S.; Seto, E. HDAC6 modulates cell motility by altering the acetylation level of cortactin Mol. Cell 2007, 27, 197-213
6. Govindarajan, N.; Rao, P.; Burkhardt, S.; Sananbenesi, F.; Schluter, O. M.; Bradke, F.; Lu, J. R.; Fischer, A. Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimers disease EMBO Mol. Med. 2013, 5, 52-63
7. Kalin, J. H.; Bergman, J. A. Development and therapeutic implications of selective histone deacetylase 6 inhibitors J. Med. Chem. 2013, 56, 6297-6313
8. Zhang, L.; Sheng, S.; Qin, C. The role of HDAC6 in Alzheimers disease J. Alzheimers Dis. 2013, 33, 283-295
9. Dallavalle, S.; Pisano, C.; Zunino, F. Development and therapeutic impact of HDAC6-selective inhibitors Biochem. Pharmacol. 2012, 84, 756-765
10. Thaler, F.; Mercurio, C. Towards selective inhibition of histone deacetylase isoforms: what has been achieved, where we are and what will be next ChemMedChem 2014, 9, 523-536
11. Wong, J. C.; Hong, R.; Schreiber, S. L. Structural biasing elements for in-cell histone deacetylase paralog selectivity J. Am. Chem. Soc. 2003, 125, 5586-5587
12. Santo, L.; Hideshima, T.; Kung, A. L.; Tseng, J. C.; Tamang, D.; Yang, M.; Jarpe, M.; van Duzer, J. H.; Mazitschek, R.; Ogier, W. C.; Cirstea, D.; Rodig, S.; Eda, H.; Scullen, T.; Canavese, M.; Bradner, J.; Anderson, K. C.; Jones, S. S.; Raje, N. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma Blood 2012, 119, 2579-2589
13. Smil, D. V.; Manku, S.; Chantigny, Y. A.; Leit, S.; Wahhab, A.; Yan, T. P.; Fournel, M.; Maroun, C.; Li, Z. M.; Lemieux, A. M.; Nicolescu, A.; Rahil, J.; Lefebvre, S.; Panetta, A.; Besterman, J. M.; Deziel, R. Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 688-692
14. Butler, K. V.; Kalin, J.; Brochier, C.; Vistoli, G.; Langley, B.; Kozikowski, A. P. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A J. Am. Chem. Soc. 2010, 132, 10842-10846
15. Lee, J. H.; Mahendran, A.; Yao, Y. S.; Ngo, L.; Venta-Perez, G.; Choy, M. L.; Kim, N.; Ham, W. S.; Breslow, R.; Marks, P. A. Development of a histone deacetylase 6 inhibitor and its biological effects Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 15704-15709
16. Jochems, J.; Boulden, J.; Lee, B. G.; Blendy, J. A.; Jarpe, M.; Mazitschek, R.; Van Duzer, J. H.; Jones, S.; Berton, O. Antidepressant-like properties of novel HDAC6-selective inhibitors with improved brain bioavailability Neuropsychopharmacology 2014, 39, 389-400
17. Wagner, F. F.; Olson, D. E.; Gale, J. P.; Kaya, T.; Weiwer, M.; Aidoud, N.; Thomas, M.; Davoine, E. L.; Lemercier, B. C.; Zhang, Y. L.; Holson, E. B. Potent and selective inhibition of histone deacetylase 6 (HDAC6) does not require a surface-binding motif J. Med. Chem. 2013, 56, 1772-1776
18. Yu, C. W.; Chang, P. T.; Hsin, L. W.; Chern, J. W. Quinazolin-4-one derivatives as selective histone deacetylase-6 inhibitors for the treatment of Alzheimers disease J. Med. Chem. 2013, 56, 6775-6791
19. Kalin, J. H.; Butler, K. V.; Akimova, T.; Hancock, W. W.; Kozikowski, A. P. Second-generation histone deacetylase 6 inhibitors enhance the immunosuppressive effects of Foxp3+ T-regulatory cells J. Med. Chem. 2012, 55, 639-651
20. Tang, G.; Wong, J. C.; Zhang, W.; Wang, Z.; Zhang, N.; Peng, Z.; Zhang, Z.; Rong, Y.; Li, S.; Zhang, M.; Yu, L.; Feng, T.; Zhang, X.; Wu, X.; Wu, J. Z.; Chen, L. Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors J. Med. Chem. 2014, 57, 8026-8034
21. Suzuki, T.; Kouketsu, A.; Itoh, Y.; Hisakawa, S.; Maeda, S.; Yoshida, M.; Nakagawa, H.; Miyata, N. Highly potent and selective histone deacetylase 6 inhibitors designed based on a small-molecular substrate J. Med. Chem. 2006, 49, 4809-4812
22. Ertl, P.; Rohde, B.; Selzer, P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties J. Med. Chem. 2000, 43, 3714-3717
23. Wong, J. C.; Guo, L.; Peng, Z.; Zhang, W.; Zhang, N.; Lai, W.; Zhang, Z.; Zhang, C.; Zhang, X.; Song, S.; Pan, D.; Xie, C.; Li, J.; Ning, Z.; Lu, X.; He, Y.; Chen, L. Application of p21 and klf2 reporter gene assays to identify selective histone deacetylase inhibitors for cancer therapy Bioorg. Med. Chem. Lett. 2011, 21, 110-116
24. Nielsen, T. K.; Hildmann, C.; Dickmanns, A.; Schwienhorst, A.; Ficner, R. Crystal structure of a bacterial class 2 histone deacetylase homologue J. Mol. Biol. 2005, 354, 107-120
25. Novotny-Diermayr, V.; Sangthongpitag, K.; Hu, C. Y.; Wu, X. F.; Sausgruber, N.; Yeo, P.; Greicius, G.; Pettersson, S.; Liang, A. L.; Loh, Y. K.; Bonday, Z.; Goh, K. C.; Hentze, H.; Hart, S.; Wang, H. S.; Ethirajulu, K.; Wood, J. M. SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer Mol. Cancer Ther. 2010, 9, 642-652